Tourillon Caroline, Mahe Julien, Baron Aurélie, Lambert Aude, Yélehé-Okouma Mélissa, Veyrac Gwenaelle, Jolliet Pascale
Clinical Pharmacology Department, Institute of Biology, CHU Nantes, Nantes, France.
Clinical Pharmacology Department, Institute of Biology, CHU Nantes, Nantes, France,
Int Arch Allergy Immunol. 2019;178(2):159-166. doi: 10.1159/000493581. Epub 2018 Nov 28.
Proton pump inhibitors (PPIs) can trigger immediate-type hypersensitivity reactions (HSRs). Three main patterns of cross-reactivity have been identified: reactions to a single PPI, selective cross-reactions, and cross-reactions with all PPIs. Several hypotheses have been advanced, but no consensus has been reached.
We sought to identify immediate-type hypersensitivity cross-reactions to PPIs using real-world data about hypersensitivity testing from French pharmacovigilance cases.
Potentially relevant immediate-type HSRs reported from January 1985 to February 2015 were extracted from the French pharmacovigilance database using a standardized MedDRA query (SMQ). Cases describing skin tests or oral provocation tests (OPTs) performed with several PPIs that yielded at least one positive result were included.
The SMQ extracted 2,119 cases, 38 of which were included in our study. Data collected from skin tests and OPTs indicated cross-reactions with all PPIs (n = 1), reactions to a single PPI (n = 14), or selective cross-reactions (n = 23). Esomeprazole, omeprazole, and pantoprazole concerned 78% of all selective cross-reactions. In more than half of the cases (55.3%), only 2 PPIs were tested.
To the best of our knowledge, this PPI cross-reactivity study is the largest to date in terms of population size, describing 38 immediate-type HSRs to PPIs explored by skin tests or OPTs. This paucity of data belies the lack of standardized procedures for PPI hypersensitivity testing. It is likely that PPI HSR workups in everyday clinical practice are often incomplete. Further research to gain insight into selective cross-reactions between PPIs is needed. In the meantime, thorough workups should be completed when a PPI is suspected to have triggered an HSR, instead of routine contraindication to all PPIs.
质子泵抑制剂(PPI)可引发速发型超敏反应(HSR)。已确定三种主要的交叉反应模式:对单一PPI的反应、选择性交叉反应以及与所有PPI的交叉反应。已提出多种假说,但尚未达成共识。
我们试图利用来自法国药物警戒病例的超敏反应检测实际数据,确定对PPI的速发型超敏交叉反应。
使用标准化的MedDRA查询(SMQ),从法国药物警戒数据库中提取1985年1月至2015年2月报告的潜在相关速发型HSR。纳入描述使用多种PPI进行皮肤试验或口服激发试验(OPT)且至少有一个阳性结果的病例。
SMQ提取了2119例病例,其中38例纳入我们的研究。从皮肤试验和OPT收集的数据表明存在与所有PPI的交叉反应(n = 1)、对单一PPI的反应(n = 14)或选择性交叉反应(n = 23)。埃索美拉唑、奥美拉唑和泮托拉唑涉及所有选择性交叉反应的78%。在超过一半的病例(55.3%)中,仅检测了2种PPI。
据我们所知,这项PPI交叉反应研究是迄今为止在人群规模方面最大的研究,描述了通过皮肤试验或OPT探索的38例对PPI的速发型HSR。数据匮乏掩盖了PPI超敏反应检测缺乏标准化程序的问题。日常临床实践中PPI HSR检查可能常常不完整。需要进一步研究以深入了解PPI之间的选择性交叉反应。与此同时,当怀疑PPI引发HSR时,应完成全面检查,而不是对所有PPI进行常规禁忌。